1) Deutscher Bundestag Drucksache 16/12000, Bericht des Ausschusses für Bildung, Forschung und Technikfolgenabschätzung.
Zukunftsreport Individualisierte Medizin und Gesundheitssystem (http://dip21.bundestag.de/dip21/btd/16/120/1612000.pdf) 2) Heimpel H, Wendt F. Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. Helv Med Acta.
1968 ; 34:103-115
3) Crookston JH, Crookston MC, Burnie KL, et al. Hereditary erythroblastic multinuclearity associated with a positive acidifi ed-
serum test: a type of congenital dyserythropoietic anaemia. Br J Haematol. 1969; 17:11-26
4) Wickramasinghe SN. Congenital dyserythropoietic anaemias: clinical features, haematological morphology and new bioche-
mical data. Blood Rev. 1998; 12:178-200
5) Delaunay J, Iolascon A. The congenital dyserythropoietic anaemias. Baillieres Best Pract Res Clin Haematol. 1999; 12:691-705
6) Heimpel H, Iolascon, A. Congenital dyserythropoietic anemia in Disorders ofhomeostasis, erythrocytes, erythropoiesis (eds.
Beaumont,C., Beris,Ph., Beuzard,Y. & Brugnara,C.) 178-201 (European School of Haematology, Paris, 2009 7) Heimpel H, Anselstetter V, Chrobak L, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance,
and prognosis based on long-term observation. Blood. 2003; 102:4576-4581
8) Heimpel H, Kellermann K, Neuschwander N, et al. The morphological diagnosis of congenital dyserythropoietic anemia:
Results of a quantitative analysis of peripheral blood and bone marrow cells. Haematologica. Im Druck 9) Queisser W, Spiertz E, Jost E, Heimpel H. Proliferation disturbances of erythroblasts in congenital dyserythropoietic anemia
type I and II. Acta Haematol. 1971; 45:65-76
10) Denecke J, Kranz C, Nimtz M, et al. Characterization of the N-glycosylation phenotype of erythrocyte membrane proteins in
congenital dyserythropoietic anemia type II (CDA II/HEMPAS). Glycoconj J. 2008; 25:375-382
11) Schwarz K, Iolascon A, Verissimo F, et al. Mutations affecting the secretory COPII coat component SEC23B cause congenital
dyserythropoietic anemia type II. Nat Genet. 2009; 41:936-40
12) Bianchi P, Fermo E, Vercellati C, et al. Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the
SEC23B gene. Hum Mutat. 2009; 30:1292-1298
13) Iolascon A, Russo R, Esposito MR, et al. Molecular analysis of forty two CDAII patients: New mutations in the SEC23B gene.
Search for a genotype-phenotype relationship. Haematologica, Im Druck 14) Daniels G, Reid ME. Blood groups: the past 50 years. Transfusion 2010; 50:281-289
15) Daniels G. et al. International Society of Blood Transfusion committee on terminology for red cell surface antigens: Macao
report. Transfusion 2009; 96:153-156
16) Westhoff CM. Molecular testing for transfusion medicine. Current Opinion in Hematology 2006; 13: 471-475
17) Reid ME. Applications in DNA-based assays in blood group antigen and antibody identifi cation. Transfusion 2003; 43:1748-
18) Flegel WA. Blood group genotyping in Germany. Transfusion 2007; 47:47S-53S
19) Veldhuisen B, van der Schoot, CE, de Haas GM. Blood group genotyping: from patient to high throughput donor screening.
Vox Sanguinis 2009; 97:198-206
20) Quill E. Blood-maching goes genetic. Science 2008; 319:1478-1479
21) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) Deutscher
Ärzte-Verlag 2007 (ISBN 978-3-7691-1250-4) 22) Avent ND et al. The BloodGen project: toward mass-scale comprehensive genotyping of blood donors in the European Union
and beyond. Transfusion 2007; 47:40S-46S
23) Hashmi G. Red blood cell antigen phenotype by DNA analysis. Transfusion 2007; 47:60S-63S
24) Wagner FF, Döscher A, Bittner R, Petershofen EK. Identifying donors with specifi c antigen combinations by multiplex PCR
and pooled capillary electrophoresis [abstract]. Transfus Med Hemother 2007; 34 (Suppl.1) Haemo_14_2010_15_juni_literatur_ohne.indd 72 Haemo_14_2010_15_juni_literatur_ohne.indd 72 25) Wagner FF, Bittner R, Petershofen EK, Doescher A, Müller TH. Cost-effi cient sequence-specifi c priming-polymerase chain
reaction screening for blood donors with rare phenotypes. Transfusion 2008; 48:1169-1173
26) Grootkerk-Tax MG, Soussan AA, de Haas M, Maaskant-van Wijk PA, van der Schoot CE. Evaluation of prenatal RHD typing
strategies on cell-free fetal DNA from maternal plasma. Transfusion 2006; 46:2142-2148
27) Legler TJ et al. Prediction of fetal RhD and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reac-
tion. Transfus Apher Sci 2002; 27:217-23
28) Grootkerk-Tax MG, Maaskant-van Wijk PA, van Drunen J., van der Schoot CE. The highly variable RH locus in non-white
persons hampers RHD zygosity determination but yields more insight into RH-related evolutionary events. Transfusion 2005; 45:327-337
29) Flegel WA. How I manage donors and patients with a weak D phenotype. Current Opinion in Hematology 2006; 13:476-483
30) Flegel WA, von Zabern I, Wagner FF. Six year´s experience performing RHD genotyping to confi rm D- red blood cell units in
Germany for preventing anti-D immunizations. Transfusion 2009; 49:465-71
31) Daniels G. Functions of red cell surface proteins. Vox Sanguinis 2007; 93:331-340
32) Mohandas N, Gallagher PG. Red cell membrane: past, present, and future. Blood 2008; 112:3939-3948
33) Bessler M, Schaefer A, Keller P. Paroxysmal nocturnal hemoglobinuria: insights from recent advances in molecular biology.
Transfus Med Rev 2001; 15:255-267
34) Nydegger UE et al. Histo-blood group antigens as allo- and autoantigens. Ann N Y Acad Sci 2005; 1050:40-51
35) Greinacher A, Bux J, Salama A. Autoimmune Thrombozytopenie, Neutropenie und Hämolyse. Internist 2009; 50: 276-290
36) Ouwehand WH, Navarrete C. The Molecular Basis of Blood Cell Alloantigens. In Molecular Hematology, 2nd edition, Provan
D, Gribben JG (eds), Blackwell Publishing Ltd, 2007; 225-240 37) Lucas GF, Metcalfe P. Platelet and granulocyte glycoprotein polymorphisms. Transfus Med 2000; 10: 157-174
38) Nguyen XD, Dugrillon A, Beck C, Kerowgan M, Klüter H. A novel method for simultaneous analysis of specifi c platelet antibo-
dies: SASPA. Br J Haematol 2004; 127: 552-560
39) Curtis BR. Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet
disorders. Semin Thromb Hemost 2008; 34: 539-548
40) Hurd CM, Cavanagh G, Schuh A, Ouwehand WH, Metcalfe P. Genotyping for platelet-specifi c antigens: techniques for the
detection of single nucleotide polymorphisms. Vox Sang 2002; 83: 1-12
41) Bugert P, Lese A, Meckies J, Zieger W, Eichler H, Klüter H. Optimized sensitivity of allele-specifi c PCR for prenatal typing of
human platelet alloantigen single nucleotide polymorphisms. Biotechniques 2003; 35: 170-174
42) McBride S. Real-Time PCR assays for high-throughput human platelet antigen typing. In DNA and RNA profi ling in human
blood, Bugert P (ed), Humana Press, Totowa, NJ. Methods in Molecular Biology 2009; 496: 39-49
43) Bugert P, McBride S, Smith G, Dugrillon A, Klüter H, Ouwehand WH, Metcalfe P. Microarray based genotyping for blood
groups; comparison of gene array and nuclease assay techniques using HPA as a model. Transfusion 2005; 45: 654-659
44) Bux J. Human neutrophil alloantigens. Vox Sang 2008; 94: 277-285
45) Nguyen XD, Flesch B, Sachs UJ, Kroll H, Klüter H, Müller-Steinhardt M. Rapid screening of granulocyte antibodies with a
novel assay: Flow cytometric granulocyte immunofl uorescence test. Transfusion 2009; 49: 2700-2708
46) Greinacher A, Wesche J, Hammer E, Fürll B, Völker U, Reil A, Bux J. Characterization of the human neutrophil alloantigen-3a.
Nat Med 2010; 16: 45-48
47) Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factor VIII and IX. Haemophilia 2006, 12 (Suppl. 6), 15-22
48) Schneppenheim R (2004). Molecular genetics of von Willebrand disease. Hamostaseologie; 24:37-43
49) Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective
collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 432–438
Haemo_14_2010_15_juni_literatur_ohne.indd 73 Haemo_14_2010_15_juni_literatur_ohne.indd 73 50) Geisen C, Watzka M, Sittinger K et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability
of oral anticoagulation. Thromb Haemost 2005; 94: 773–779
51) Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J
Med 2005; 352: 2285–2293
52) Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and
inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745–1751
53) Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause wafarin resistance and multiple coagulation factor defi cien-
cy type 2. Nature 2004; 427: 537–541
54) Oldenburg J, Bevans CG, Fregin A, Geisen C, et al. Current pharmacogenetic developments in oral anticoagulation therapy:
the infl uence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98(3): 570-8
55) Reid ME, Lomas-Francis C. The blood group Antigen FactsBook. Elsevier 2002 (ISBN 0-12-586585-6)
56) Daniels G. Human blood groups. Blackwell 2002 (ISBN 0-632-056460)
57) Daniels G. The molecular genetics of blood group polymorphism. Hum Genet 2009; 126:729-742
58) Daniels G. Structure and function of red cell surface antigens. ISBT Science Series 2006; 1: 3-8
Additional Links
Blood group mutation database: www.bioc.aecom.yu.edu/bgmut/index.htm Working Group "Rare Blood Groups“of Section V (Immunohaematology/Gene Technology) of DGTI: www.seltene-blutgruppen.de Haemo_14_2010_15_juni_literatur_ohne.indd 74 Haemo_14_2010_15_juni_literatur_ohne.indd 74

Source: http://www.blutspende.de/en/isbt/pdf/Molecular-diagnostics.pdf

management of prostate cancer: an overview

Radiation Management Of Prostate Cancer An OvervieW Table of Contents THE PROSTATE GLAND ….…………………………………………….……….….2 PROSTATE CANCER.……………………………………….………………….……2 PATIENT EVALUATION AND DIAGNOSTIC TESTING …………….….….3-5 MANAGEMENT OF PROSTATE CANCER AN OVERVIEW OF APPROACHES


THIS IS A GUIDANCE DOCUMENT AND SHOULD NOT BE INTERPRETED AS A REPLACEMENT TO THE RULES. The rules for classifying and coding industrial wastes andhazardous wastes may be found in 30 Texas AdministrativeCode (TAC) Sections (§§) 335.501-.521 (Subchapter R). Texas Commission on Environmental QualityTexas Commission on Environmental Quality Kathleen Hartnett White, Chairman R. B. “R

© 2010-2017 Pharmacy Pills Pdf